Apellis Pharmaceuticals Inc (APLS)
27.73
+0.24
(+0.87%)
USD |
NASDAQ |
Nov 21, 16:00
27.73
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals Profit Margin (Quarterly): -29.19% for Sept. 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -29.19% |
| June 30, 2024 | -18.86% |
| March 31, 2024 | -38.55% |
| December 31, 2023 | -60.51% |
| September 30, 2023 | -127.0% |
| June 30, 2023 | -128.5% |
| March 31, 2023 | -396.4% |
| December 31, 2022 | -732.4% |
| September 30, 2022 | -867.2% |
| Date | Value |
|---|---|
| June 30, 2022 | -955.6% |
| March 31, 2022 | -966.1% |
| December 31, 2021 | -245.4% |
| September 30, 2021 | -3.46K% |
| June 30, 2021 | -35.18K% |
| March 31, 2021 | |
| December 31, 2020 | 31.31% |
| September 30, 2020 | -21.01K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-35.18K%
Minimum
Jun 2021
31.31%
Maximum
Dec 2020
-4.01K%
Average
-320.9%
Median
Profit Margin (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 14.22% |
| Ionis Pharmaceuticals Inc | -105.0% |
| EyePoint Pharmaceuticals Inc | -279.0% |
| Cassava Sciences Inc | -- |
| Macrogenics Inc | 50.86% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -104.7% |
| Return on Assets | -29.46% |
| Return on Invested Capital | -52.47% |
| Gross Profit Margin (Quarterly) | 82.95% |
| Operating Margin (Quarterly) | -24.02% |
| Return on Net Operating Assets | -55.90% |